August 3, 2020

The Niche

Knoepfler lab stem cell blog

Masaya Nakamura

2 min read

Japan is a leader in stem cell and regenerative medicine research, and in particular in clinical translation toward the bedside. Induced pluripotent stem cell (IPSC)-based investigational therapies are rightly an area of focus in Japan given their invention by Nobel Laureate Shinya Yamanaka. Small clinical studies based on IPSC have been initiated there for several diseases including related to vision loss and Parkinson’s Disease. David Cyranoski over at Nature reports on a new, different stem cell clinical effort in Japan for vision loss with …Read More

2 min read

A cool new paper is out in Stem Cell Reports describing long-term tumorigenicity of human induced pluripotent stem cells (IPSC or IPS cells). See graphical abstract. The potential tumorigenicity of IPSC is a major concern when teams around the world are translating IPSC technology to the bedside. Past studies including one from my own lab have shown that there are some parallels between cellular reprogramming to make IPSC and tumorigenicity. MYC has often been viewed as the likely culprit but this paper expands the potentially …Read More